An overview of polymyositis and dermatomyositis

Muscle and Nerve

Volumn 51, Issue 5, 2015, Pages 638-656

  Findlay, Andrew R ^a   Goyal, Namita A ^a   Mozaffar, Tahseen ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dermatomyositis; Inclusion body myositis; Inflammatory myopathy; Myositis specific autoantibodies; Polymyositis

Indexed keywords

ABATACEPT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; METHOTREXATE; MYOGLOBIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SIFALIMUMAB; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT;

ANTI SYNTHETASE SYNDROME; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE CLASSIFICATION; ELECTROMYOGRAPHY; ENZYME BLOOD LEVEL; GENETICS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KINESIOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; OVERLAP SYNDROME; PATHOGENESIS; PHYSIOTHERAPY; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; PREVALENCE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; BIOLOGICAL PRODUCTS; DERMATOMYOSITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POLYMYOSITIS; PREVALENCE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84928167599     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24566     Document Type: Review

References (158)

1. Dalakas M. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;325:1487-1498.
2. Dalakas M, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-982.
3. Bohan A, Peter J. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-407.
4. Bohan A, Peter J. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-347.
5. Hoogendijk J, Amato A, Lecky B, Choy E, Lundberg I, Rose M, et al. 119th ENMC International Workshop: Trial Design in Adult Idiopathic Inflammatory Myopathies, with the Exception of Inclusion Body Myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337-345.
6. Rider L, Miller F. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011;305:183-190.
7. Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 2011;23:595-604.
8. Mohassel P, Mammen A. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: a review. Muscle Nerve 2013;48:477-483.
9. Stenzel W, Goebel H-H, Aronica E. Immune-mediated necrotizing myopathies-a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol 2012;38:632-646.
10. Dimachkie M, Barohn R. Inclusion body myositis. Curr Neurol Neurosci Rep 2013;13:321.
11. Mastaglia F, Phillips B. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin N Am 2002;28:723-741.
12. Smoyer Tomic K, Amato A, Fernandes A. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskel Disord 2012;13:103.
13. Bernatsky S, Joseph L, Pineau C, Belisle P, Boivin J, Banerjee D, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis 2009;68:1192-1196.
14. Furst D, Amato A, Iorga SR, Gajria K, Fernandes A. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 2012;45:676-683.
15. van der Meulen M, Bronner I, Hoogendijk J, Burger H, van Venrooij W, Voskuyl A, et al. Polymyositis: an overdiagnosed entity. Neurology 2003;61:316-321.
16. Amato A, Barohn R. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009;80:1186-1193.
17. Prieto S, Grau J. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010;9:330-334.
18. Furst D, Amato A, Iorga S, Bancroft T, Fernandes A. Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population. Muscle Nerve 2012;46:496-505.
19. Griggs R, Askanas V, DiMauro S, Engel A, Karpati G, Mendell J, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-713.
20. Greenberg S. Inflammatory myopathies: evaluation and management. Sem Neurol 2008;28:241-249.
21. Finsterer J, Frank M, Krexner E. Steroid-responsive dropped-head-syndrome due to polymyositis. Joint Bone Spine 2010;77:485-486.
22. Slobodin G, Rozenbaum M, Weller B, Boulman N, Rosner I. Dropped head: an unusual presentation of dermatomyositis. J Rheumatol 2005;32:1174-1175.
23. Marie I, Dominique S, Remy-Jardin M, Hatron P, Hachulla E. Interstitial lung diseases in polymyositis and dermatomyositis [in French]. La Rev Med Interne 2001;22:1083-1096.
24. Ebert E. Review article: The gastrointestinal complications of myositis. Aliment Pharmacol Ther 2010;31:359-365.
25. de Merieux P, Verity M, Clements P, Paulus H. Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis. Arthritis Rheum 1983;26:961-968.
26. Amato A, Barohn R. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009;80:1060-1068.
27. Margo JB. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010;146:36-40.
28. Khan S, Christopher-Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin N Am 2011;37:143-158.
29. Santmyire-Rosenberger B, Dugan E. Skin involvement in dermatomyositis. Curr Opin Rheumatol 2003;15:714-722.
30. Sontheimer R. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 2002;20:387-408.
31. Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 2012;14:264-274.
32. Danko K, Ponyi A, Constantin TS, Borgulya GB, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 2004;83:35-42.
33. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 2012;14:275-285.
34. Dalakas M. Review: An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011;37:226-242.
35. Sultan S, Isenberg D. Re-classifying myositis. Rheumatology (Oxford, England) 2010;49:831-833.
36. Zong M, Lundberg I. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011;7:297-306.
37. Amato A, Griggs R. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003;61:288-289.
38. Chahin N, Engel A. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418-424.
39. Mozaffar T. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000;68:472-478.
40. Mammen A. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nature Rev Neurol 2011;7:343-354.
41. Katzap E, Barilla-LaBarca M-L, Marder G. Antisynthetase syndrome. Curr Rheumatol Reports 2011;13:175-181.
42. Isenberg D, Black C. ABC of rheumatology. Raynaud's phenomenon, scleroderma, and overlap syndromes. BMJ (Clin Res Ed) 1995;310:795-798.
43. Clements P, Furst D, Campion D, Bohan A, Harris R, Levy J, et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum 1978;21:62-71.
44. Sharp G, Irvin W, Tan E, Gould R, Holman H. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-159.
45. Rosales X, Chu M-L, Shilling C, Wall C, Pastores G, Mendell J. Fidelity of gamma-glutamyl transferase (GGT) in differentiating skeletal muscle from liver damage. J Child Neurol 2008;23:748-751.
46. Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry 2009;80:904-908.
47. Fardeau MD, Desguerre I. Diagnostic workup for neuromuscular diseases. In: Dulac O, Lassonde M, Sarnat HB, editors. Handbook of clinical neurology. Vol. 113. Paris: Elsevier; 2013. p 1291-1297.
48. Gallardo E, Rojas-Garcia R, de Luna N, Pou A, Brown R, Illa I. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001;57:2136-2138.
49. Lai CH, Melli G, Chang YJ, Skolasky R, Corse A, Wagner K, et al. Open muscle biopsy in suspected myopathy: diagnostic yield and clinical utility. Eur J Neurol 2010;17:136-142.
50. Prayson R. Diagnostic yield associated with multiple simultaneous skeletal muscle biopsies. Am J Clin Pathol 2006;126:843-848.
51. Kissel J, Mendell J, Rammohan K. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314:329-334.
52. Emslie-Smith A, Engel A. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990;27:343-356.
53. Arahata K, Engel A. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208.
54. De Visser M, Emslie-Smith A, Engel A. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989;94:181-192.
55. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000;68:472-478.
56. Bradley W. Polymyositis: an overdiagnosed entity. Neurology 2004;63:402.
57. Hengstman G, van Engelen B. Polymyositis: an overdiagnosed entity. Neurology 2004;63:402.
58. van der Pas J, Hengstman G, ter Laak H, Borm G, van Engelen B. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004;75:136-139.
59. Hewer E, Goebel H. Myopathology of non-infectious inflammatory myopathies-the current status. Pathol Res Pract 2008;204:609-623.
60. Salaroli R, Baldin E, Papa V, Rinaldi R, Tarantino L, De Giorgi L, et al. Validity of internal expression of the major histocompatibility complex class I in the diagnosis of inflammatory myopathies. J Clin Pathol 2012;65:14-19.
61. Jain A, Sharma M, Sarkar C, Bhatia R, Singh S, Handa R. Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies. Arch Pathol Lab Med 2007;131:1070-1076.
62. Blume G, Pestronk A, Frank B, Johns D. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain 1997;120:39-45.
63. Christopher-Stine L. Neurologists are from Mars. Rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2010;22:623-626.
64. Love L, Leff R, Fraser D, Targoff I, Dalakas M, Plotz P, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-374.
65. Targoff I, Miller F, Medsger T, Oddis C. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997;9:527-535.
66. Targoff I. Myositis specific autoantibodies. Curr Rheumatol Rep 2006;8:196-203.
67. Gunawardena H, Betteridge Z, McHugh N. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford, England) 2009;48:607-612.
68. Madan V, Chinoy H, Griffiths C, Cooper R. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exper Dermatol 2009;34:561-565.
69. Michito H. Autoantibodies to aminoacyl-tRNA synthetases. Intern Med 2005;44:527-528.
70. Kalluri M, Sahn S, Oddis C, Gharib S, Christopher-Stine L, Danoff S, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009;135:1550-1556.
71. Larman H, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73:408-418.
72. Adams E, Chow C, Premkumar A, Plotz P. The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics 1995;15:563-574.
73. Schulze M, Kotter I, Ernemann U, Fenchel M, Tzaribatchev N, Claussen C, et al. MRI findings in inflammatory muscle diseases and their noninflammatory mimics. AJR Am J Roentgenol 2009;192:1708-1716.
74. Kimball A, Summers R, Turner M, Dugan E, Hicks J, Miller F, et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis Rheum 2000;43:1866-1873.
75. Maillard S, Jones R, Owens C, Pilkington C, Woo P, Wedderburn L, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford, England) 2004;43:603-608.
76. Park J, Vansant J, Kumar N, Gibbs S, Curvin M, Price R, et al. Dermatomyositis: correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease. Radiology 1990;177:473-479.
77. Brown V, Pilkington C, Feldman B, Davidson J; Network for Juvenile Dermatomyositis (PReS). An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford, England) 2006;45:990-993.
78. Hernandez R, Sullivan D, Chenevert T, Keim D. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol 1993;161:359-366.
79. Adler R, Garofalo G. Ultrasound in the evaluation of the inflammatory myopathies. Curr Rheumatol Rep 2009;11:302-308.
80. Simon D, Ringel S, Sufit R. Clinical spectrum of fascial inflammation. Muscle Nerve 1982;5:525-537.
81. Pestronk A, Kos K, Lopate G, Al-Lozi M. Brachio-cervical inflammatory myopathies: clinical, immune, and myopathologic features. Arthritis Rheum 2006;54:1687-1696.
82. Rojana-Udomsart A, Fabian V, Hollingsworth P, Walters S, Zilko P, Mastaglia F. Paraspinal and scapular myopathy associated with scleroderma. J Clin Neuromuscul Dis 2010;11:213-222.
83. Smith A, Urbanits S, Blaivas M, Grisold W, Russell J. Clinical and pathologic features of focal myositis. Muscle Nerve 2000;23:1569-1575.
84. Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978;28:8-17.
85. Kissel J, Halterman R, Rammohan K, Mendell J. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991;48:26-30.
86. Pestronk A, Schmidt R, Choksi R. Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve 2010;42:53-61.
87. Karpati G, Carpenter S, Melmed C, Eisen A. Experimental ischemic myopathy. J Neurol Sci 1974;23:129-161.
88. Hathaway P, Engel W, Zellweger H. Experimental myopathy after microarterial embolization: comparison with childhood X-linked pseudohypertrophic muscular dystrophy. Arch Neurol 1970;22:365-378.
89. Grundtman C, Tham E, Ulfgren A-K, Lundberg I. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 2008;58:3224-3238.
90. Park J, Olsen N, King L, Vital T, Buse R, Kari S, et al. Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum 1995;38:68-77.
91. Ulfgren A-K, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris H, et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004;50:1586-1594.
92. Grundtman C, Bruton J, Yamada T, Ostberg T, Pisetsky D, Harris H, et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 2010;24:570-578.
93. Reed A, Ernste F. The inflammatory milieu in idiopathic inflammatory myositis. Curr Rheumatol Rep 2009;11:295-301.
94. Englund P, Lindroos E, Nennesmo I, Klareskog L, Lundberg I. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001;159:1263-1273.
95. Fasth A, Dastmalchi M, Rahbar A, Salomonsson S, Pandya J, Lindroos E, et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol 2009;183:4792-4799.
96. Bettelli E, Korn T, Oukka M, Kuchroo V. Induction and effector functions of T(H)17 cells. Nature 2008;453:1051-1057.
97. Page G, Sattler A, Kersten S, Thiel A, Radbruch A, Miossec P. Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol 2004;164:409-417.
98. Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003;137:125-133.
99. Waschbisch A, Schwab N, Ruck T, Stenner M-P, Wiendl H. FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 2010;225:137-142.
100. Banica L, Besliu A, Pistol G, Stavaru C, Ionescu R, Forsea A-M, et al. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009;42:41-49.
101. Oddis C, Reed A, Aggarwal R, Rider L, Ascherman D, Levesque M, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2012;65:314-324.
102. Vandenbroucke E, Grutters J, Altenburg J, Boersma W, ter Borg E, van den Bosch JM. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009;29:1499-1502.
103. Greenberg S, Pinkus J, Pinkus G, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-678.
104. McNiff J, Kaplan D. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol 2008;35:452-456.
105. Confalonieri P, Bernasconi P, Megna P, Galbiati S, Cornelio F, Mantegazza R. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 2000;59:164-169.
106. Raju R, Dalakas M. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005;128:1887-1896.
107. Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg I. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007;56:674-687.
108. Lundberg I, Ulfgren A, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:865-874.
109. Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S, et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol 2002;14:917-924.
110. Chiu W, Fann M, Weng N-P. Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines. J Immunol 2006;177:7802-7810.
111. Scuderi F, Mannella F, Marino M, Provenzano C, Bartoccioni E. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol 2006;176:9-15.
112. Eloranta M-L, Barbasso Helmers S, Ulfgren A-K, Ronnblom L, Alm G, Lundberg I. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007;56:3112-3124.
113. Walsh R, Kong S, Yao Y, Jallal B, Kiener P, Pinkus J, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784-3792.
114. Norton W, Velayos E, Robison L. Endothelial inclusions in dermatomyositis. Ann Rheum Dis 1970;29:67-72.
115. Grimley P, Davis G, Kang Y, Dooley J, Strohmaier J, Hoofnagle J. Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon. Lab Invest 1985;52:638-649.
116. Greenberg S, Sanoudou D, Haslett J, Kohane I, Kunkel L, Beggs A, et al. Molecular profiles of inflammatory myopathies. Neurology 2002;59:1170-1182.
117. Greenberg S, Higgs B, Morehouse C, Walsh R, Kong S, Brohawn P, et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immunity 2012;13:207-213.
118. Haller O, Kochs G. Interferon-induced Mx proteins: dynamin-like GTPases with antiviral activity. Traffic 2002;3:710-717.
119. Salajegheh M, Kong S, Pinkus J, Walsh R, Liao A, Nazareno R, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010;67:53-63.
120. Gregorio C, Granzier H, Sorimachi H, Labeit S. Muscle assembly: a titanic achievement? Curr Opin Cell Biol 1999;11:18-25.
121. Banker B. Dermatomyostis of childhood, ultrastructural alteratious of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol 1975;34:46-75.
122. Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996;97:2905-2910.
123. Bradshaw E, Orihuela A, McArdel S, Salajegheh M, Amato A, Hafler D, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007;178:547-556.
124. Salajegheh M, Pinkus J, Amato A, Morehouse C, Jallal B, Yao Y, et al. Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 2010;42:576-583.
125. Dalakas M. Pathogenesis and therapies of immune-mediated myopathies. Autoimmunity Rev 2012;11:203-206.
126. O'Hanlon T, Carrick D, Targoff I, Arnett F, Reveille J, Carrington M, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine 2006;85:111-127.
127. Mammen A, Gaudet D, Brisson D, Christopher-Stine L, Lloyd T, Leffell M, et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res 2012;64:1233-1237.
128. Betteridge Z, Gunawardena H, Chinoy H, North J, Ollier W, Cooper R, et al. Collaboration UKAOMI. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 2009;68:1621-1625.
129. Mierau R, Dick T, Bartz-Bazzanella P, Keller E, Albert E, Genth E. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 1996;39:868-876.
130. Shamim E, Rider L, Pandey J, O'Hanlon T, Jara L, Samayoa E, et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002;46:1885-1893.
131. Rojana-Udomsart A, Mitrpant C, James I, Witt C, Needham M, Day T, et al. Analysis of HLA-DRB3 alleles and supertypical genotypes in the MHC Class II region in sporadic inclusion body myositis. J Neuroimmunol 2013;254:174-177.
132. O'Hanlon T, Rider L, Schiffenbauer A, Targoff I, Malley K, Pandey J, et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum 2008;58:3239-3246.
133. Mamyrova G, O'Hanlon T, Sillers L, Malley K, James-Newton L, Parks C, et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008;58:3941-3950.
134. Dalakas M. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheum 2010;6:129-137.
135. Dalakas M. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Options Neurol 2011;13:311-323.
136. Distad B, Amato A, Weiss M. Inflammatory myopathies. Curr Treat Options Neurol 2011;13:119-130.
137. Morganroth P, Kreider M, Werth V. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res 2010;62:1496-1501.
138. Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 2011;30:1021-1028.
139. Oddis C, Sciurba F, Elmagd K, Starzl T. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999;353:1762-1763.
140. Brandao M, Marinho A. Idiopathic inflammatory myopathies: definition and management of refractory disease. Autoimmun Rev 2011;10:720-724.
141. Villalba L, Hicks J, Adams E, Sherman J, Gourley M, Leff R, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41:392-399.
142. Dalakas M, Illa I, Dambrosia J, Soueidan S, Stein D, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
143. Wang D, Shu X, Tian X, Chen F, Zu N, Ma L, et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. Clin Rheumatol 2012;31:801-806.
144. Sem M, Molberg O, Lund M, Gran J. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford, England) 2009;48:968-971.
145. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 2010;62:1328-1334.
146. Furlan A, Botsios C, Ruffatti A, Todesco S, Punzi L. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine 2008;75:366-367.
147. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani C, Einarsdottir H, Helmers S, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-1677.
148. Amato A, Tawil R, Kissel J, Barohn R. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011;70:427-436.
149. Higgs B, Zhu W, Morehouse C, White W, Brohawn P, Guo X, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2013;73:256-262.
150. Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheum Rep 2012;14:244-251.
151. Wiesinger G, Quittan M, Aringer M, Seeber A, Volc-Platzer B, Smolen J, et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Rheumatology 1998;37:196-200.
152. Alexanderson H, Dastmalchi M, Esbjornsson-Liljedahl M, Opava C, Lundberg I. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007;57:768-777.
153. Medsger T, Robinson H, Masi A. Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum 1971;14:249-258.
154. Schiopu E, Phillips K, MacDonald P, Crofford L, Somers E. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 2012;14:R22.
155. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006;25:234-239.
156. Marie I, Menard J-F, Hachulla E, Cherin P, Benveniste O, Tiev K, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Sem Arthritis Rheum 2011;41:48-60.
157. Bronner I, van der Meulen M, de Visser M, Kalmijn S, van Venrooij W, Voskuyl A, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006;65:1456-1461.
158. Marie I, Hatron P, Levesque H, Hachulla E, Hellot M, Michon-Pasturel U, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine 1999;78:139-147.